AptarGroup (ATR) – Analysts’ Recent Ratings Changes

AptarGroup (NYSE: ATR) recently received a number of ratings updates from brokerages and research firms:

  • 10/27/2017 – AptarGroup had its “hold” rating reaffirmed by analysts at KeyCorp.
  • 10/18/2017 – AptarGroup was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “For third-quarter 2017, AptarGroup expects earnings to be in the range of 77-97 cents. The mid point of the guidance reflects 4.8% improvement year over year. Its focus on execution of growth strategy will help customers to grow their business with innovative dispensing solutions. The company has implemented a commercial excellence program to boost sales and marketing capability in Beauty + Home segment. AptarGroup also has positive record of earnings surprises in the last few quarters. Moreover, the stock outperformed the industry in the past year. However, AptarGroup continues to face headwinds in Brazil due to tough economic situation. Weak consumer spending will hit AptarGroup, curbing demand for its products. Additional interest expense, higher raw material costs and foreign exchange volatility will also hurt the company’s results in the near term. Further, its estimates have gone down over the past three months.”
  • 10/17/2017 – AptarGroup was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $100.00 price target on the stock. According to Zacks, “For third-quarter 2017, AptarGroup expects earnings to be in the range of 77–97 cents. The mid point of the guidance reflects 4.8% improvement year over year. Its focus on execution of growth strategy will help customers to grow their businesses with innovative dispensing solutions. The company has implemented a commercial excellence program to boost sales and marketing capability in its Beauty + Home segment. The Pharma segment continues to benefit from strong demand across its portfolio of devices, mainly for devices used for allergy treatment, decongestions and ophthalmics, along with components sold to the injectables markets. AptarGroup's Mega Airless acquisition was a key element of its strategy to expand portfolio and accelerate growth in the airless systems markets. The company has outperformed the industry over the past year.”
  • 10/12/2017 – AptarGroup had its “hold” rating reaffirmed by analysts at Robert W. Baird. They now have a $85.00 price target on the stock.
  • 10/2/2017 – AptarGroup was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “For third-quarter 2017, AptarGroup expects earnings to be in the range of 77–97 cents. The mid point of the guidance reflects 4.8% improvement year over year. Its focus on execution of growth strategy will help customers to grow their businesses with innovative dispensing solutions. The company has implemented a commercial excellence program to boost sales and marketing capability in its Beauty + Home segment. However, AptarGroup continues to face headwinds in Brazil due to tough economic situation. Absence of some significant custom tooling sales will drag Pharma segment's sales growth in the next quarter. In addition, weak consumer spending will hit AptarGroup, curbing demand for its products. Additional interest expense, higher raw material costs and foreign exchange volatility will also hurt the company’s results in the near term. Its estimates have gone down lately.”
  • 9/22/2017 – AptarGroup had its “hold” rating reaffirmed by analysts at KeyCorp.

Shares of AptarGroup, Inc. (NYSE:ATR) traded up 0.53% during midday trading on Wednesday, reaching $87.53. 173,317 shares of the company’s stock traded hands. The firm has a market cap of $5.49 billion, a PE ratio of 25.74 and a beta of 0.96. AptarGroup, Inc. has a 52-week low of $70.43 and a 52-week high of $90.79. The company has a 50 day moving average of $87.41 and a 200 day moving average of $84.90.

AptarGroup (NYSE:ATR) last released its quarterly earnings data on Thursday, October 26th. The industrial products company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.80 by $0.03. AptarGroup had a net margin of 9.24% and a return on equity of 16.82%. The firm had revenue of $624.33 million for the quarter, compared to analyst estimates of $599.31 million. During the same period last year, the firm earned $0.82 earnings per share. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. On average, equities analysts predict that AptarGroup, Inc. will post $3.35 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 22nd. Shareholders of record on Wednesday, November 1st will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.47%. The ex-dividend date is Tuesday, October 31st. AptarGroup’s dividend payout ratio (DPR) is 37.43%.

In related news, insider Salim Haffar sold 18,130 shares of the firm’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $86.49, for a total transaction of $1,568,063.70. Following the transaction, the insider now directly owns 39,556 shares of the company’s stock, valued at $3,421,198.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Monnas Giovanna Kampouri sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $82.13, for a total transaction of $164,260.00. Following the transaction, the director now directly owns 6,469 shares in the company, valued at $531,298.97. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by company insiders.

AptarGroup, Inc is a provider of a range of packaging, dispensing and sealing solutions, primarily for the beauty, personal care, homecare, prescription drug, consumer healthcare, injectables, food and beverage markets. The Company has manufacturing facilities located throughout the world, including North America, Europe, Asia and South America.

What are top analysts saying about AptarGroup Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AptarGroup Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit